Research tools
Biomarker articles covering signals used to study, predict, monitor, or measure Crohn's disease and IBD activity or treatment response.
Page 1 of 3 · 123 articles
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
Treg/Th17 balance is a central immune mechanism implicated in IBD pathogenesis; understanding how microbes, metabolites, and tissue context control that balance could inform new biomarkers and targeted therapies.
This review summarizes human evidence that pesticides in the diet could affect the gut microbiome and may be linked to gastrointestinal outcomes including IBD; strongest consistent signals were for organochlorine...
IBD-U means no clear Crohn’s or ulcerative colitis diagnosis yet — that uncertainty can affect treatment decisions and follow-up. The review highlights tests that may help clarify diagnosis and stresses that many...
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
A blood biomarker that reliably distinguishes UC from CD could help when endoscopy or histology are inconclusive and improve diagnostic confidence. This paper reports a candidate autoantibody (anti‑integrin αvβ6) with...
The paper identifies a gut microbiome–driven pathway (flagellin → TLR5 → IL-15 → ARA) that might link intestinal microbial changes to systemic inflammation seen in long COVID and other immune-mediated diseases,...
If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.
Quantitative, rapid stool tests could make it easier to track intestinal inflammation without central lab delays. If translated to clinical use, SERS-enhanced lateral-flow assays might allow more frequent, point-of-care...
The study points to serum protein panels and tissue expression of glypican-6 (GPC6) as potential tools to diagnose or predict intestinal strictures in Crohn disease, which could help detect fibrosis earlier and guide...
A blood test that more reliably distinguishes UC from CD could reduce diagnostic uncertainty and help guide appropriate long‑term management for people with colonic inflammatory bowel disease.
The paper suggests a new molecular link—low ALIX expression—to inflammatory cell death (pyroptosis) that might help explain mucosal inflammation in ulcerative colitis. If validated, that pathway could point to biomarkers...
If validated, blood protein signatures that appear years before symptoms could help identify people at higher risk of Crohn’s disease and point to lifestyle or dietary measures that alter early biology.
People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...
Identifies specific gut bacteria and fecal bilirubin metabolites that may link microbial loss to increased oxidative burden in IBD; suggests new biomarker candidates and targets for functional follow-up.
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
The study uses generative AI and microbiome/RNA data to search for biomarkers of intestinal fibrosis in Crohn’s disease, which could help spot scarring earlier and potentially prevent worsening complications like...
This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.
IBD increases risk of osteoporosis; identifying blood proteins that predict later bone loss could help flag higher-risk patients and reveal biological links between gut inflammation and bone health.
Many people with IBD try dietary changes to manage symptoms. This review summarizes what published adult studies report and points toward whole-food and Mediterranean-style patterns as commonly supported approaches.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Infliximab. The original article is from Journal of Genetic Engineering and...
Understanding how the gut virome shapes regulatory T cells could reveal new biomarkers or therapeutic targets for IBD and related systemic immune diseases. This may help explain unexplained flares or individual...
Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
Identifies gene and microbiome patterns linked to progression from inflammation to irreversible bowel fibrosis in Crohn’s disease, which could eventually help predict who is at higher risk and inform prevention...
Distinct circulating immune signatures could help differentiate active UC from CD and suggest disease-specific pathways that might guide future biomarkers or therapies.
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
Fibrosis (irreversible bowel scarring) is a major cause of surgery in Crohn’s disease. This study points to molecular and microbiome patterns that may help predict or distinguish fibrosis from active inflammation, which...
Fibrosis (irreversible bowel scarring) is a major cause of surgery in Crohn’s disease. Identifying molecular and microbial markers tied to fibrosis could eventually help predict who’s at higher risk and guide earlier,...
The work points to measurable molecular and microbial patterns that may help distinguish treatable inflammation from progressive fibrosis and suggests AI could aid in building predictive tools from limited samples —...
The probe targets azoreductase-driven hypoxia, a mechanism linked to ulcerative colitis and other hypoxia-associated diseases; a reliable real-time imaging method could help research and eventually guide treatments.
The study links shared gene-expression patterns between IBD and ankylosing spondylitis and highlights STAT3 as a potential shared biomarker or therapeutic target, which could be relevant for understanding overlapping...
Researchers used genetics plus single-cell sequencing and ELISA to prioritize plasma protein ratios that may causally relate to ulcerative colitis. If validated in larger studies, such biomarkers could help with...
If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...
Researchers found antisense RNA activity in gut microbes that tracks with active inflammation in IBD and with faecal calprotectin — suggesting a new microbial signal that might help understand or monitor disease...
RDW is a cheap, routinely measured blood parameter; if it reliably reflects IBD presence or activity, it could be an easy additional tool to help detect flares or support assessment without extra testing.
If you have IBD and take biologic therapy plus other medicines, inflammation and anti-cytokine treatment may change how your other drugs are metabolized. This review discusses ways researchers are trying to predict and...
A blood antibody (anti-integrin αvβ6) was associated with relapse risk in UC and may help predict who stays in long-term remission, which could affect monitoring and treatment planning.
The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...
Researchers and clinicians are exploring how fucose metabolism affects gut barrier function, immunity, and microbiota — processes central to IBD and colorectal cancer. If validated, fucosylation biomarkers or treatments...
Researchers and clinicians looking for blood- or tissue-based molecular tests for IBD may find these integrated transcriptomic analyses useful because they identify candidate diagnostic biomarkers and highlight shared...
Early, noninvasive biomarkers could help detect ulcerative colitis and related colorectal cancer risk sooner. This study identifies four serum-accessible proteins with promising diagnostic accuracy in the reported...
PSC occurring with IBD changes cancer risk and surveillance needs: patients can have extensive but asymptomatic colitis and a higher colorectal and biliary cancer risk. The review outlines gaps in diagnosis, monitoring,...
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...
Environmental exposures from agricultural chemicals may affect the gut microbiome and intestinal inflammation, which could be one factor influencing IBD risk or flares. Understanding these links could point to preventive...
Intestinal fibrosis is a serious complication of long-standing ulcerative colitis. Identifying NET-related biomarkers (IL1RN, MUC1, SERPINA1) could help researchers develop better diagnostic tools or treatments targeting...
Identifying an RNF213-marked Treg subset may help researchers understand immune mechanisms active in UC and could lead to new biomarker or therapeutic targets in the future.
